^
Association details:
Biomarker:NTRK3 fusion
Cancer:Biliary Tract Cancer
Drug Class:Trk inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Excerpt:
NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].